Artificial intelligence is entering the nutraceutical formulation workflow at every stage, from bioactive discovery and microbiome-targeted design through pharmacokinetic simulation and full product lifecycle management.
At Vitafoods Europe 2026 (May 5-7, Fira Barcelona Gran Via), five technology companies demonstrated platforms that apply machine learning, digital twin modelling, and generative AI to problems historically solved by months of bench work, manual regulatory cross-referencing, and trial-and-error ingredient selection.
MeNow AI uses a proprietary database of 1.2 million natural compounds to predict bioactive synergies in silico. Enbiosis builds genome-scale metabolic models of the gut microbiome to design condition-specific nutraceutical premixes. Formulaite generates manufacturer-ready master batch records from plain-English product briefs and validates them with PBPK digital twin simulations. Centric Software embeds AI-driven formulation management within a full product lifecycle management (PLM) platform connected to 220 global regulatory libraries. Siftlink combines molecular modelling with patent analytics to guide R&D strategy for food, nutraceutical, and pharmaceutical innovators.
This article examines each platform’s formulation AI capabilities, supporting technologies, and positioning for supplement brands, contract manufacturers, and ingredient suppliers evaluating AI-assisted product development.
Content Overview
- MeNow AI: Bioactive Discovery and Synergy Prediction at Scale
- Enbiosis: Microbiome Digital Twins for Condition-Specific Formulation
- Formulaite: From Product Brief to Manufacturer-Ready Formula in Hours
- Centric Software: AI-Enhanced PLM for Nutraceutical Product Lifecycle
- Siftlink: Molecular Modelling Meets Patent Intelligence for R&D Strategy
- Comparison Table: AI Formulation Platforms for Nutraceuticals
- FAQs
- Key Takeaways
- Sources
MeNow AI: Bioactive Discovery and Synergy Prediction at Scale
MeNow AI is an Israeli biotech company founded in 2021 in Ramat Gan, Israel, led by CEO Dr. Hilla Ben-Hamo Arbel (biotech engineering and neuroscience) and CTO Dr. Coralie Ebert (chemoinformatics and molecular modelling). The company operates a multidisciplinary team of biologists, chemists, data scientists, and biophysicists.
AI-Driven Formulation: The Search MeNow Platform
MeNow’s core offering is Search MeNow, an AI platform built on a proprietary database of over 1.2 million natural compounds sourced from more than 60,000 organisms, with 99% of the data classified as proprietary.[1] The platform does not operate as a single “formulation AI” module but integrates formulation intelligence across three interconnected capabilities:
- Bioactive discovery. The AI identifies novel bioactive compounds from botanical sources using pattern recognition on molecular structures. It predicts mechanisms of action, identifies molecular targets, and assesses potential bioactive claims – all without requiring initial laboratory testing.[1]
- Synergy prediction. At a systems biology level, the platform analyses molecular datasets to predict where multiple bioactive compounds amplify each other’s effects. This moves beyond single-ingredient analysis to model how combinations interact, enabling formulators to design blends optimised for efficacy rather than relying on individual-ingredient stacking.[2]
- Botanical extract analysis. The AI predicts the molecular composition of plant extracts, providing insights into both bioactivity profiles and safety characteristics. This supports extraction process optimisation and informs formulation decisions on ingredient selection and dosing.[1]
Additional Technologies
Technical marketing intelligence. MeNow integrates chemical databases with market trend analysis, social media monitoring, and consumer feedback data. The platform analyses competitive landscapes and emerging scientific trends to support product positioning and regulatory strategy, claiming up to 91% reduction in marketing and R&D research time.[2]
Sustainability and upcycling optimisation. The platform identifies multiple valuable compounds from single plant sources, supporting circular waste management and extraction efficiency. This enables ingredient suppliers to maximise the value extracted from botanical raw materials while reducing waste streams.
Validated Results
MeNow reports a 70% reduction in resource use for ingredient R&D and a 5x decrease in formulation development costs across its client base.[2] Published case studies include a collaboration with Colgate that achieved a 75% reduction in development time for a plant-based gingivitis treatment, and a partnership with Les Bois that produced what the company describes as “one of the first cosmetics formulations developed using AI,” validated through double-blind clinical trials.[3] Additional clients in the nutraceutical and functional food space include KSM66 (Ixoreal/Baldwa Group), for which the platform conducted a safety profile analysis of ashwagandha root versus leaf, identifying liver-toxic molecules in the leaf fraction.[3]
Enbiosis: Microbiome Digital Twins for Condition-Specific Formulation
Enbiosis is a biotechnology company headquartered in London (Canary Wharf), with a US office in Cambridge, Massachusetts, and a planned R&D branch in Denmark’s Medicon Valley. Founded by Omer Ozkan (CEO), Ozkan Ufuk Nalbantoglu (CTO), and Aycan Gundogdu, the company positions itself as the developer of the world’s first digital twin and AI-powered nutraceutical formulation engine.[4]
AI-Driven Formulation: The Enbiosis 2.0 Platform
The Enbiosis 2.0 platform, launched at Vitafoods Europe 2026, represents the company’s pivot from personalised consumer nutrition (its 1.0 product) to B2B formulation discovery.[4] The formulation engine operates through three technical layers:
- Genome-scale metabolic models (GEMs). Built from a proprietary dataset of over 200,000 microbiome samples, these models are digital representations of gut bacterial metabolism that simulate how specific food-grade ingredients are processed by the microbiome.[5]
- AI retrosynthesis engine. The system works backward from a desired health outcome (such as increased tear production for dry eye) to identify which food-grade precursor molecules will drive the required biological response. It determines the ingredient combination that will produce the target metabolites through microbial metabolism.[4]
- Digital twin simulation. Before clinical testing, the platform simulates how a candidate formulation will interact with the microbiome of a target patient population. This replaces the traditional correlational approach (bacterium X is associated with condition Y) with a mechanistic one (ingredient A is metabolised by bacterium X to produce compound B, which addresses condition Y).[4]
The output is a standardised powder premix containing 12-15 bioactives, designed as a ready-to-license formulation that manufacturers can produce as capsules, sachets, or functional food ingredients under their own brand.[4]
Additional Technologies
Personalised microbiome analysis (Enbiosis 1.0). The consumer-facing platform uses next-generation sequencing (NGS) whole-genome analysis of stool samples to generate personalised diet recommendations, food scores, and supplement guidance. The system assesses overall microbiome resilience with a claimed 90.8% accuracy, identifies 25+ keystone bacterial species, and connects microbiome composition to functional health risk profiles.[6,7]
Probiotic and prebiotic strain matching. A smart scoring system matches specific probiotic strains and prebiotic substrates to individual microbiome profiles, enabling personalised supplementation recommendations.[5]
See Enbiosis’ Video on How Enbiosis Designs Microbiome-Driven Formulations:
Scientific Validation
Enbiosis has published peer-reviewed results across multiple journals. A randomised controlled trial (RCT) with 121 IBS patients, published in The American Journal of Gastroenterology, demonstrated that the AI-personalised diet outperformed the low FODMAP diet, achieving 85% symptom improvement versus 78% for low FODMAP, with significant increases in microbial diversity.[8] Additional peer-reviewed publications in Gut Microbes (78% IBS treatment success rate), Journal of Clinical Medicine (83% success in chronic constipation), and Biomedical Signal Processing and Control support the platform’s clinical credibility.[6,9]
A 20-participant pilot study on dry eye disease reported progressive improvement in tear production over eight weeks, with the company claiming approximately 50% better performance than cyclosporine, the standard prescription drug.[6] Clinical trials across ophthalmology, urology, GI/IBD, and metabolic conditions are planned for mid-2026, with dermatology and neurology/cognition trials scheduled for 2027.[5]
Table 1. Enbiosis published clinical evidence summary
| Study | Design | Population | Key Finding | Journal |
| IBS personalised diet vs. low FODMAP | RCT, 6 weeks | 121 patients | Personalised diet: IBS-SSS change -112.7 vs. -99.9 (low FODMAP); effective across all IBS subtypes | Am. J. Gastroenterol. (2024) |
| IBS microbiome modulation | Intervention study | IBS patients | 78% treatment success rate | Gut Microbes (2022) |
| Chronic constipation | Intervention study | Constipation patients | 83% success; AI diet outperforms laxatives | J. Clin. Med. (2022) |
| Dry eye disease | Pilot, 8 weeks | 20 participants | ~50% better tear production than cyclosporine | Unpublished / company data |
Formulaite: From Product Brief to Manufacturer-Ready Formula in Hours
Formulaite is a Mountain View, California-based startup founded in 2025. Led by CEO Milind Upadhyay (AI and chemistry engineering; former Lead Product Developer at Molecular Quantum Solutions), the company is a member of the NVIDIA Inception Program and operates with a small team focused on AI-driven nutraceutical, herbal supplement, and cosmetic formulation.[10]
AI-Driven Formulation: The Formulaite Agent
The core product is an AI R&D agent that converts plain-English product descriptions into manufacturer-ready formulations. The workflow operates in two primary stages:[10]
Stage 1: Formulaite (Concept to Formula). The user describes product goals in natural language – target health benefit, demographic, delivery format, market positioning. The AI agent synthesises clinical research, peer-reviewed scientific literature, and traditional pharmacopoeia (including Ayurvedic references) to generate a complete master batch record. The output includes:
- Evidence-based ingredient and dosage recommendations with peer-reviewed citations
- Multi-jurisdiction regulatory compliance screening (FDA, FSSAI/AYUSH, EU Novel Foods, Health Canada)
- Competition analysis and sales potential forecasting
- Novelty assessment for patent potential
Stage 2: Simulaite (Digital Twin Validation). This validation layer applies three computational methods to the generated formulation:[10]
- Physiologically based pharmacokinetic (PBPK) modelling. Simulates how ingredients dissolve, absorb, distribute, metabolise, and excrete in virtual patient populations.
- Graph neural networks. Predict molecular interactions targeting liver enzymes, plasma proteins, and gut wall transport mechanisms.
- Quantum chemistry stability modelling. Estimates shelf life and identifies potential degradation pathways.
The Simulaite engine also models ingredient synergies and incompatibilities (such as piperine enhancing curcumin absorption) and tests formulations across diverse virtual patient demographics varying by ethnicity, gender, age, and health conditions.[10]
Additional Technologies
Multi-jurisdiction regulatory screening. Regulatory compliance is embedded in the formulation step rather than treated as a downstream check, covering FDA, FSSAI, AYUSH, EU, and Health Canada frameworks simultaneously.
IP ownership model. Formulaite operates on a 100% client IP ownership basis – the platform functions as a tool, and the company does not claim co-development rights over generated formulations.[10]
Target Applications
The platform serves supplement brands without in-house R&D, contract development and manufacturing organisations (CDMOs) accelerating formulation services, and ingredient manufacturers seeking to demonstrate applications for their raw materials. Clients include HempStreet, Vasu Healthcare, Peakfinity Labs, and Black Label Ingredients.[10] The self-serve platform launched in early 2026 with a free tier available at app.formulaite.ai.
See Formulaite’s Video on how to Build Breakthrough Clinically-Backed Formulas:
Centric Software: AI-Enhanced PLM for Nutraceutical Product Lifecycle
Centric Software, headquartered in Campbell, California, is a subsidiary of Dassault Systemes and a provider of product lifecycle management (PLM) software. Founded in 2004, the company originally served the fashion and apparel industry before expanding into food, beverage, cosmetics, and process industries starting in 2019. Centric claims approximately 400 customers bringing USD 700 billion worth of products to market annually across all industries.[11]
AI-Driven Formulation: Embedded Intelligence Within PLM
Centric does not offer a standalone formulation AI tool. Instead, AI capabilities are embedded directly into the PLM workflow, augmenting how formulation teams develop, refine, and manage products. Key AI applications include:[12]
- Smart search on historical formulations. AI-powered retrieval surfaces relevant past recipe trials and similar raw ingredient data during product development, accelerating formulation by building on existing institutional knowledge.
- AI-driven compliance optimisation. Automated regulatory checks run against formulations in real time, flagging non-compliance as formulators adjust ingredient lists and dosing.
- Automated impact analysis. When ingredients or formulations change, the system identifies all affected products, suppliers, and regulatory requirements across the portfolio, preventing downstream disruptions.
Formulation Management Capabilities
Centric PLM for Food & Beverage manages the end-to-end product lifecycle from concept and formula development through packaging, quality management, supplier collaboration, and nutritional labelling.[11] For nutraceutical teams specifically:
- Formulation teams develop and refine products while managing dosage, stability, and bioavailability data within a single platform.
- Label templates auto-populate with formulation, allergen, nutrition, and regulatory data from the PLM system and connected databases.
- A compliance engine allows users to create, approve, and review compliance rules for ingredients with step-by-step formulation checks.[12]
Additional Technologies
FoodChain ID integration. A partnership with FoodChain ID (established October 2023) provides access to 220 global regulatory libraries via a compliance analysis connector. Product developers see the immediate regulatory impact of ingredient changes as they formulate, covering cross-country compliance requirements in real time.[13]
Product experience management (Centric PXM). Following the EUR 220 million acquisition of Contentserv in February 2025, Centric added AI-powered product information management, digital asset management, and content syndication across 1,000+ sales channels.[14]
Sustainability and tariff management. The platform includes ESG regulation compliance tools, environmental metrics tracking, and automated reporting at product, project, and portfolio levels. Recent 2025 features address tariff impact analysis for food and beverage products.[12]
Industry Validation
Centric Software was named in Gartner’s 2025 Market Guide for PLM in Food & Beverage and recognised as a Market Leader in the QKS Group 2025 SPARK Matrix for PLM in Process Industries.[11] Nutraceutical client NHCO Nutrition Laboratories (France) manages 70+ products and approximately 1,000 ingredients on the platform.[15] The company reports up to 60% decrease in time to market and up to 50% improvement in productivity across its food and beverage client base.[11]
Table 2. Centric Software PLM – key modules relevant to nutraceutical manufacturers
| Module | Function |
| Formulation management | Recipe development, ingredient management, dosage and stability tracking |
| Compliance engine | Step-by-step regulatory checks per ingredient, cross-jurisdiction screening |
| FoodChain ID connector | Access to 220 global regulatory libraries; real-time impact analysis |
| Material management | Supplier specifications, safety data sheets, certificate tracking |
| Packaging and proofing | Label creation, artwork management, regulatory label compliance |
| Quality management | HACCP, FSSC 22000 workflow integration, audit management |
| Centric PXM | Product information syndication across 1,000+ channels |
Siftlink: Molecular Modelling Meets Patent Intelligence for R&D Strategy
Siftlink SA is a Swiss life sciences AI company based at the Biopole campus in Epalinges (near Lausanne), Switzerland. Founded in June 2021 by Dr. Yiannis Kourmpetis, whose PhD in statistical modelling in bioinformatics at Wageningen University produced a protein function prediction method that ranked first globally in the 2010 Critical Assessment of Functional Annotation (CAFA) competition.[16]
AI-Driven Formulation: Molecular Prediction and Strategic Intelligence
Siftlink’s platform combines molecular science with business and patent intelligence to guide R&D decisions for food, nutraceutical, and pharmaceutical companies. The company has built over 1,000 machine learning models to predict how molecules behave and uncover links between proteins, chemicals, and their biological functions.[16] The core technology stack includes:
- Molecular modelling. Predictive models for molecular behaviour and interactions, enabling in silico assessment of ingredient functionality before bench testing.
- Genome screening. Analysis of genetic data to extract functional insights relevant to ingredient performance and biological targets.
- Big data from omics. Integration of proteomics, genomics, and related datasets to build a comprehensive picture of ingredient-biology interactions.[17]
Additional Technologies
Patent analytics. Siftlink mines patent literature to map competitive landscapes, identify white space for new filings, and protect client IP portfolios. This positions the platform not just as an R&D tool but as a strategic advisory system that connects scientific innovation to intellectual property protection.[17]
Business analytics. Market trend analysis and competitive landscape assessment complement the scientific capabilities, providing R&D teams with commercial context for formulation and ingredient decisions.
Sensi – AI conversational agent. Siftlink’s client-facing AI agent, Sensi, is available 24/7 and provides targeted, fact-based insights drawn from the company’s data and machine learning infrastructure. The system is designed for focused, actionable intelligence rather than broad data reporting – it requests specific information from users to improve its models and recommendations.[18]
Positioning
Siftlink differentiates through its cross-domain data foundation: curated scientific data (molecular, omics), patent data, and business analytics unified in a single platform. The company serves both large multinationals and smaller organisations, offering R&D strategy guidance from a base within Switzerland’s premier life sciences campus. The founder’s background in globally ranked computational protein prediction lends scientific credibility to the platform’s molecular modelling claims.[16]
Comparison: AI Formulation Platforms for Nutraceuticals
Take a look at our infographic comparing three approaches to nutraceutical formulation:
Table 3. Feature comparison of AI formulation platforms
| Feature | MeNow AI | Enbiosis | Formulaite | Centric Software | Siftlink |
| Headquarters | Ramat Gan, Israel | London, UK | Mountain View, USA | Campbell, USA (Dassault Systemes) | Epalinges, Switzerland |
| Founded | 2021 | 2018 | 2025 | 2004 | 2021 |
| Core AI capability | Bioactive discovery and synergy prediction | Microbiome digital twin formulation | Concept-to-formula AI agent with PBPK validation | AI-embedded PLM with formulation management | Molecular modelling + patent analytics |
| Formulation AI approach | Predicts bioactive compound synergies from 1.2M+ compound database | Retrosynthesis engine designs formulations via gut microbiome metabolic models | Generates master batch records from natural language briefs | Smart search on historical formulations; AI compliance checking | 1,000+ ML models predicting molecular behaviour |
| Proprietary data scale | 1.2M compounds, 60,000 organisms | 200,000+ microbiome samples | Clinical literature and pharmacopoeia synthesis | Connected to 220 regulatory libraries (FoodChain ID) | 1,000+ purpose-built ML models |
| Digital twin / simulation | In silico bioactivity prediction | Genome-scale metabolic models of gut microbiome | PBPK + graph neural networks + quantum chemistry | Automated impact analysis across product portfolio | Molecular modelling and genome screening |
| Regulatory coverage | Not a primary feature | Not a primary feature | FDA, FSSAI/AYUSH, EU Novel Foods, Health Canada | 220 global regulatory libraries; real-time compliance | Not a primary feature |
| Published clinical evidence | Client case studies (Colgate, Les Bois, KSM66) | Peer-reviewed RCTs (Am. J. Gastroenterol., Gut Microbes, J. Clin. Med.) | No published studies | Client ROI metrics (NHCO, Wild Foods) | No published studies |
| Target users | Ingredient suppliers, functional food companies | Supplement manufacturers, functional food brands | Brands without in-house R&D, CDMOs | Established F&B and nutra manufacturers | R&D teams, innovation strategists |
| Business model | B2B SaaS + consulting | B2B formulation licensing | Self-serve SaaS (free tier available) | Enterprise PLM SaaS | B2B consulting + platform |
| Key differentiator | Scale of proprietary natural compound data | Causal microbiome modelling (not correlational) | No formulation scientist required; plain-language input | End-to-end PLM with embedded AI, not a point solution | Molecular science + IP strategy in one platform |
FAQs
What is AI-driven nutraceutical formulation?
AI-driven nutraceutical formulation uses machine learning models, molecular simulations, and large proprietary datasets to automate or augment the process of selecting ingredients, predicting efficacy, checking regulatory compliance, and validating formulation stability. These platforms replace or accelerate traditional bench work and manual literature review with computational predictions that can generate or refine formulations in hours rather than months.
How does formulation AI differ from traditional supplement formulation?
Traditional formulation relies on a formulation scientist’s domain knowledge, iterative bench testing, manual regulatory cross-referencing, and trial-and-error stability assessment. AI-driven platforms accelerate each of these steps computationally. For example, synergy prediction (MeNow AI) replaces sequential ingredient testing, digital twin simulation (Enbiosis, Formulaite) replaces early-stage clinical feasibility assessment, and automated compliance engines (Centric Software) replace manual regulatory review against multiple jurisdictions.
Can AI formulation tools replace human formulation scientists?
Current platforms augment rather than replace human expertise. Tools like Formulaite are designed for teams without in-house formulation scientists, generating initial formulations that still require manufacturing validation. Platforms like MeNow AI and Siftlink position their AI as a complement to human decision-making, surfacing insights and predictions that scientists then evaluate. Centric Software’s PLM approach embeds AI into existing workflows managed by human teams.
What types of data power these AI formulation platforms?
Data sources vary by platform. MeNow AI uses a database of 1.2 million natural compounds from 60,000 organisms. Enbiosis draws on 200,000+ microbiome samples to build genome-scale metabolic models. Formulaite synthesises peer-reviewed clinical literature and pharmacopoeia. Centric Software connects to 220 global regulatory libraries via FoodChain ID. Siftlink integrates omics data, patent literature, and business analytics.
Are AI-generated formulations clinically validated?
Validation varies significantly across platforms. Enbiosis has published peer-reviewed clinical data in journals including The American Journal of Gastroenterology and Gut Microbes. MeNow AI has validated predictions through client case studies with in vitro and clinical confirmation. Formulaite offers in silico validation through PBPK modelling and digital twin simulation but has not published independent clinical studies. Centric Software and Siftlink focus on product development efficiency and R&D strategy rather than direct clinical validation of formulations.
How do these platforms handle regulatory compliance?
Regulatory integration ranges from none to comprehensive. Centric Software offers the deepest regulatory coverage through its FoodChain ID connector (220 global regulatory libraries) and built-in compliance engine. Formulaite screens formulations against FDA, EU Novel Foods, FSSAI/AYUSH, and Health Canada frameworks during the generation step. MeNow AI, Enbiosis, and Siftlink do not position regulatory compliance as a primary platform feature.
What is a microbiome digital twin in the context of nutraceutical formulation?
A microbiome digital twin, as implemented by Enbiosis, is a computational model that simulates how the gut microbiome of a target population metabolises specific food-grade ingredients. Using genome-scale metabolic models built from real microbiome sequencing data, the platform predicts which precursor molecules will be converted into therapeutic metabolites by gut bacteria. This enables formulation design based on causal mechanisms rather than correlational associations between bacteria and health outcomes.
Key Takeaways
- AI formulation platforms for nutraceuticals span a wide functional range, from bioactive compound discovery (MeNow AI) and microbiome-targeted design (Enbiosis) to concept-to-formula automation (Formulaite), enterprise product lifecycle management (Centric Software), and R&D strategy with IP protection (Siftlink).
- Digital twin technology is a common thread: MeNow AI simulates bioactive interactions in silico, Enbiosis models gut microbiome metabolism, and Formulaite applies PBPK pharmacokinetic simulation – each reducing dependence on early-stage bench testing.
- Regulatory compliance integration varies significantly. Centric Software (220 regulatory libraries via FoodChain ID) and Formulaite (multi-jurisdiction screening) embed compliance into the formulation workflow. Other platforms treat regulatory assessment as a separate downstream step.
- Clinical validation maturity differs across platforms. Enbiosis leads with peer-reviewed RCTs published in gastroenterology and clinical medicine journals. MeNow AI has validated predictions through client case studies. Formulaite, Centric Software, and Siftlink rely on computational validation or operational metrics.
- Proprietary data represents the primary competitive moat for most platforms: 1.2 million compounds (MeNow AI), 200,000+ microbiome samples (Enbiosis), 220 regulatory libraries (Centric Software), and 1,000+ purpose-built ML models (Siftlink).
- For supplement brands without in-house R&D, Formulaite offers the lowest barrier to entry with its plain-language interface and free tier. For established manufacturers with complex product portfolios, Centric Software’s PLM approach provides end-to-end lifecycle management with embedded AI. For brands seeking microbiome-differentiated positioning, Enbiosis offers a clinically validated formulation licensing model.
Sources
- MeNow AI. “Our Technology.” Accessed May 13, 2026. https://www.menow.ai/tech
- MeNow AI. “Search MeNow Platform.” Accessed May 13, 2026. https://search.menow.ai/
- MeNow AI. “Case Studies.” Accessed May 13, 2026. https://www.menow.ai/case-studies
- NutraIngredients. “Enbiosis Reveals 2.0 Platform: AI-Powered Nutraceutical Discovery.” April 2, 2026. https://www.nutraingredients.com/Article/2026/04/02/enbiosis-reveals-20-platform-ai-powered-nutraceutical-discovery/
- Enbiosis. “AI Gut Microbiome Platform.” Accessed May 13, 2026. https://enbiosis.com/ai-gut-microbiome-platform/
- Enbiosis. “Clinical Studies.” Accessed May 13, 2026. https://enbiosis.com/clinical-studies/
- Enbiosis. “About Enbiosis.” Accessed May 13, 2026. https://enbiosis.com/about-enbiosis/
- NutraIngredients. “Enbiosis Finds Microbiome-Based Personalised Diet More Effective Than Low FODMAP in IBS.” May 20, 2024. https://www.nutraingredients.com/Article/2024/05/20/Enbiosis-finds-microbiome-based-personalized-diet-more-effective-than-low-FODMAP-in-IBS/
- Enbiosis. “Products.” Accessed May 13, 2026. https://enbiosis.com/product/
- Formulaite. “AI-Powered R&D Platform.” Accessed May 13, 2026. https://formulaite.ai/
- Centric Software. “Food & Beverage Industry Software.” Accessed May 13, 2026. https://www.centricsoftware.com/food-beverage/
- Centric Software. “Centric PLM Serves Up New Innovations for Food & Beverage.” PR Newswire. 2025. https://www.prnewswire.com/news-releases/centric-plm-serves-up-new-innovations-for-the-food–beverage-and-grocery-industry-to-drive-efficiency–speed-302533857.html
- Centric Software. “FoodChain ID Compliance Partnership.” Accessed May 13, 2026. https://www.centricsoftware.com/press-releases/centric-software-foodchain-id-compliance-food-cosmetics-product-development/
- Dassault Systemes. “Acquisition of Contentserv.” 2025. https://www.3ds.com/newsroom/press-releases/dassault-systemes-announces-centric-softwares-acquisition-ai-powered-pxm-solution-contentserv
- Centric Software. “NHCO Nutrition Laboratory Live with Centric PLM.” Accessed May 13, 2026. https://www.centricsoftware.com/press-releases/nhco-nutrition-laboratory-live-with-centric-plm-enhance-product-development-compliance/
- Biopole. “Siftlink SA Company Profile.” Accessed May 13, 2026. https://www.biopole.ch/company/siftlink/
- Biopole. “Unpacking the Role of AI in Scientific Innovation.” Accessed May 13, 2026. https://www.biopole.ch/story/unpacking-the-role-of-ai-in-scientific-innovation/
- Siftlink. “Sensi – AI Conversational Agent.” Accessed May 13, 2026. https://siftlink.com/sensi/
